Taysha Gene Therapies Inc. (TSHA)
NASDAQ · Healthcare
Taysha Gene Therapies Inc. annual/quarterly shareholder equity history from 2022 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Taysha Gene Therapies Inc. shareholder equity for the quarter ending December 31, 2025 were 246.9M, a 245.25% increase year-over-year.
- Taysha Gene Therapies Inc. shareholder equity for 2025 were 246.9M, a 245.25% increase from 2024.
- Taysha Gene Therapies Inc. shareholder equity for 2024 were 71.5M, a 4.55% decrease from 2023.
- Taysha Gene Therapies Inc. shareholder equity for 2023 were 74.9M, a 7796.42% increase from 2022.
- Taysha Gene Therapies Inc. shareholder equity for 2022 were 949,000.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Taysha Gene Therapies Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $247 |
| 2024 | $72 |
| 2023 | $75 |
| 2022 | $1 |
| Taysha Gene Therapies Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $247 |
| 2024-12-31 | $72 |
| 2023-12-31 | $75 |
| 2022-12-31 | $1 |
Taysha Gene Therapies Inc. Shareholder Equity — FAQ
Taysha Gene Therapies Inc. (TSHA) shareholder equity over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TSHA's shareholder equity history?
The chart and table above show Taysha Gene Therapies Inc.'s shareholder equity by year and by quarter, including the growth rate.